NC-BIOVENTUS
22.9.2020 16:32:10 CEST | Business Wire | Press release
Bioventus , a global leader in Innovations For Active Healing, is celebrating a milestone and recognizing more than 2 million treatments worldwide with DUROLANE , its single-injection, hyaluronic acid (HA) product used in the treatment of pain associated with osteoarthritis (OA). DUROLANE is the original single injection hyaluronic acid therapy, has helped patients in nearly 30 countries and is a trusted therapy for clinicians in the management of OA.
Proven safe and effective, DUROLANE has more clinical studies than any other US single-injection HA, and has also been proven to provide greater reduction in OA knee pain versus Synvisc-One® .1,2 It has longer lasting pain relief versus a steroid injection, is safe and repeated use of DUROLANE does not increase the incidence of adverse events.3,4
DUROLANE is available in its original 3ml syringe for treatment of large joints and in a 1ml syringe, known as DUROLANE SJ , to enable treatment of small joints.* Both are produced using a natural, safe and proven technology called NASHA® . This process yields a high molecular weight stabilized HA, which is a naturally occurring molecule that provides lubrication and cushioning in a normal joint.
“The US launch of DUROLANE in 2018 boosted our growth to more than 2 million treatments and we are very proud of this milestone. Still, there are many more patients to reach,” said John Nosenzo, Chief Commercial Officer, Bioventus. “In the US, more than 14 million people are afflicted with knee OA and osteoarthritis overall affects more than 240 million globally.5,6 Returning people to active lifestyles is our commitment to the market and we are pleased that DUROLANE is serving the needs of clinicians and the OA patients they treat.”
About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations For Active Healing from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the company on LinkedIn and Twitter.
Bioventus, the Bioventus logo, and DUROLANE are registered trademarks of Bioventus LLC. NASHA is a registered trademark. Synvisc-One and Synvisc are registered trademarks of Genzyme Corporation.
*DUROLANE SJ is not available in the US.
Summary of Indication for Use: DUROLANE is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g. acetaminophen. Do not inject DUROLANE in patients with knee joint infections, skin diseases, or other infections in the area of the injection site. Do not administer to patients with known hypersensitivity or allergy to sodium hyaluronate preparations. Risks can include transient pain or swelling at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Full prescribing information can be found in product labeling, at www.DUROLANE.com , or by contacting Bioventus Customer Service at 1-800-836-4080.
NOTE: The above indications presented are for the US market; indications may vary by country. Contact your local Bioventus representative or visit www.durolane.com/uk/selection for prescribing information specific to your market.
1. McGrath AF, McGrath AM, Jessop ZM, et al. A comparison of intra-articular hyaluronic acid competitors in the treatment of mild to moderate knee osteoarthritis. J Arthritis . 2013; 2(1):108. doi:10.4172/2167-7921.1000108. 2. DOF RPT-001111 3. Leighton R, Åkermark C, Therrien R, et. al. NASHA hyaluronic acid vs methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial. Osteoarthritis Cartilage . 2014; 22(1):17-25. 4. DUROLANE [package insert]. Durham, NC: Bioventus LLC; 2017. 5. Arthritis Foundation. What is osteoarthritis? Accessed February 9, 2019. www.arthritis.org/about-arthritis/types/osteoarthritis/what-is-osteoarthritis.php 6. Hawker GA. Osteoarthritis is a serious disease. Clin Exp Rheumatol . 2019;37 Suppl 120(5):3-6.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200922005067/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sitetracker and 5x5 Break the Price Barrier for Portfolio-Scale Digital Twins and Asset Intelligence23.9.2026 12:11:00 CEST | Press release
Sitetracker and 5x5 partner to bring synthetic digital twins technology to the Wireless Infrastructure market. Sitetracker and 5x5 Technologies today introduced a data-to-twin workflow that gives wireless infrastructure owners a practical, affordable path to digitizing an entire tower portfolio. The Sitetracker platform now integrates 5x5 Synthetic Twin technology, providing scalable asset intelligence at a price up to 85% less than traditional site modeling methods. Synthetic Twins leverage Sitetracker’s leading tower portfolio and operational data to create interactive 3D models of towers, rooftops and ground compounds providing tower operators with a baseline of their portfolio that can be progressively enriched as the site conditions evolve. This data when combined with Scout, Sitetracker’s Agentic AI platform, opens the opportunity for digitized workflows and unparalleled understanding of the asset portfolio. Why it matters AI-driven data demand, more spectrum deployments, and den
LTM Launches BlueVerse™ SovereignSphere™ Models to Help Enterprises Own Their AI Advantage23.9.2026 12:05:00 CEST | Press release
LTM, the Business Creativity partner to the world's largest enterprises, today launched BlueVerse™ SovereignSphere™ Models, enabling organizations to transform proprietary knowledge into AI capabilities that understand their business context and operate within their governance boundaries. BlueVerse SovereignSphere Models enable enterprises to overcome critical AI adoption challenges by lowering infrastructure costs, simplifying governance, and reducing reliance on generic AI models. It helps organizations build AI that understands their business, language, workflows, policies, and domain expertise as a native capability. Enterprises retain ownership of their models and intellectual property while benefiting from more predictable AI economics and reduced dependence on token-heavy architectures. The key offerings in the portfolio include:Sales and Marketing Pro – Delivers CRM architect-level expertise across solution design, code generation, troubleshooting, and root-cause analysis, help
Cox Capital Announces Tender Offers for Class I Shares of Blackstone Private Credit Fund and HPS Corporate Lending Fund23.9.2026 12:00:00 CEST | Press release
Offers provide a secondary cash-liquidity option for BCRED and HLEND shareholders following oversubscribed issuer repurchase programs Cox Capital Partners (“Cox Capital”) announced today that Cox Capital Retail Secondaries Fund I, LP (the “Purchaser”), a private investment fund managed by an affiliate of Cox Capital, has commenced two separate cash tender offers to purchase Class I shares of Blackstone Private Credit Fund (“BCRED”) and HPS Corporate Lending Fund (“HLEND”). Both funds recently reported that their Q3 2026 repurchase programs were substantially oversubscribed. BCRED and HLEND received repurchase requests representing an estimated 10% and 11.5%, respectively, of shares outstanding. The funds’ established frameworks generally target quarterly repurchases of 5% of shares outstanding, although the amount may be increased at the discretion of the applicable fund. Cox Capital developed its secondary program to provide shareholders with an additional path to liquidity when a fun
Three Weeks into France E-Invoicing Mandate: Sovos Hits Unparalleled Production Scale23.9.2026 10:00:00 CEST | Press release
With 170,000 registrants - 78x the registered network reach of the nearest tax compliance competitor - Sovos demonstrates unmatched production scale across direct clients and every software platform embedding its Compliance Network Sovos, the agentic tax compliance company, today announced that it has surpassed 170,000 organizations registrants across the Sovos-powered network – including both Sovos-branded and partner-branded approved service providers - using Sovos technology in France. By comparison, the nearest competitors registered fewer than 2,200 organizations each. The milestone represents a significant lead in production-grade e-invoicing, with Sovos handling transaction volumes that are many multiples higher than any other tax compliance vendor operating in France. "France represents the most complex continuous transaction controls mandate the world has seen, and we entered production on day one with our Global 2000 clients fully live," said Kevin Akeroyd, CEO, Sovos. "We ac
Thredd Partners with Velocity to Expand Global Payments Platform, Offer Stablecoin-Powered Money Movement23.9.2026 09:00:00 CEST | Press release
New capabilities will connect cards, fiat payment rails, and stablecoins through one integrated platform experience Thredd, the AI-first issuer processing platform, today announced the expansion of its payments platform to include stablecoin-powered money movement capabilities, through a partnership with Velocity, the stablecoin treasury and settlement platform bringing enterprises onchain. The initial rollout of these capabilities will focus on supporting B2B and B2B2B applications, including stablecoin-backed card programmes, cross-border payouts, global treasury flows and on-chain settlement. Thredd clients will now be able to convert between fiat currencies and supported stablecoins, send funds on-chain or through connected fiat rails, and use stablecoins for funding, payouts and settlement. “Stablecoins are rapidly becoming an important part of global payments infrastructure, but clients should not have to rebuild their payments stack to take advantage of them,” said Jim McCarthy,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom